Novavax reported $-482960000 in Operating Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Adma Biologics ADMA:US $ 16.96M 38.45M
Agenus AGEN:US $ -44.56M 9.1M
AstraZeneca AZN:LN 539M 339M
Astrazeneca AZN:US 539M 339M
Biocryst Pharmaceuticals BCRX:US $ -34.72M 15.24M
Dynavax Technologies DVAX:US $ 128.23M 97.46M
Genocea Biosciences GNCA:US $ -15.77M 2.36M
Geron GERN:US $ -27.98M 0.7M
GlaxoSmithKline GSK:LN 1.08B 1.72B
Mannkind MNKD:US $ -20.45M 0.8M
Merk MRK:US $ 4927M 642M
Minerva Neurosciences NERV:US $ -6.96M 1.02M
Moderna Inc MRNA:US 2.45B 1.78B
Novartis NVS:US $ 2228M 624M
Novavax NVAX:US $ -482.96M 692.25M
Pain Therapeutics PTIE:US $ -19917000 2.1M
Peregrine Pharmaceuticals PPHM:US $ 1.07M 2.2M
Pfizer PFE:US $ 12102M 2229M
Sarepta Therapeutics SRPT:US $ -211.13M 124.25M
Tg Therapeutics TGTX:US $ -38.94M 27.93M